New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
06:14 EDTVRTXVertex upgraded to Buy from Neutral at UBS
UBS upgraded Vertex based on increased confidence that the lumicaftor-ivacaftor combination will be successful in 2014 Phase 3 readouts in cystic fibrosis. Price target raised to $99 from $84.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
13:42 EDTVRTXVertex peak CF sales have bullish read from Royalty Pharma bet, TheStreet says
Subscribe for More Information
10:42 EDTVRTXUBS hosts a conference call with Vertex Pharmaceuticals
Subscribe for More Information
07:52 EDTVRTXInforma Business Information to hold a conference
Subscribe for More Information
07:27 EDTVRTXRoyalty Pharma acquires royalties on Vertex Pharmaceuticals CF treatments
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use